Aimed Alliance recently submitted letters of support to the Washington and Iowa legislatures urging them to swiftly pass biomarker legislation to ensure consumers have access to these necessary and informative tests. Biomarker testing plays a pivotal role in gathering personalized information essential for the disease prevention, diagnosis, and treatment. By analyzing biological specimens such as tissue and blood, practitioners can identify key biomarkers, including genetic and molecular indicators that can help inform treatment decisions and patient outcomes. The expansion of insurance coverage for biomarker testing is a critical step towards improving accessibility to this invaluable diagnostic tool. Identifying specific biomarkers allows health care practitioners to personalize treatments for individual patients, reducing unnecessary interventions and maximizing therapeutic benefits . Read our letters here and here.
Last Updated on April 1, 2024 by Aimed Alliance
